2007年2月7日
碧萝芷®比处方药物阻止血糖吸收的能力高190倍
Pycnogenol® Delays Glucose Absorption 190 Times More Potently than Prescription Medication

        新的研究实验说明了碧萝芷®是如何降低糖尿病人血糖水平的。
        New Study discovers how Pycnogenol® lowers Blood Glucose Levels in Type II Diabetes

        在即将刊登于新一期的糖尿病研究通讯和临床实践杂志上的一篇有关法国沿海松树皮提取物碧萝芷®的实验文章中写道，与处方药物相比，碧萝芷®可以将患者餐后血糖峰值来临的时间推迟190倍，实验假设病人的血糖峰值出现在餐后。实验表明，碧萝芷®在抑制碳水化合物吸收方面的效果要大大强于人工合成的处方药物阿尔法-葡萄糖苷酶抑制剂，如Precose。
        A new study to be published in an upcoming edition of the journal of Diabetes Research and Clinical Practice reveals that French maritime pine tree extract known as Pycnogenol® (pic-noj-en-all) delays the uptake of glucose from a meal 190 times more than prescription medications, preventing the typical high glucose peak in the blood stream after a meal. The study revealed the pine bark is more potent for suppressing carbohydrate absorption in diabetes than synthetic prescription alpha-glucosidase inhibitors such as Precose.

        “患II型糖尿病的患者人数越来越多，”此项实验的实验带头人Petra Hogger博士说。“这项实验对于患有II型糖尿病的患者来说很有意义，因为这项实验证明了碧萝芷®的降血糖效果要强于Precose等处方药物，同时，这也很好的佐证了其他的有关碧萝芷®对糖尿病治疗功效的实验结果。”
        "Diabetes mellitus type II is a serious disease with rising prevalence," said Dr. Petra Högger, a lead researcher of this study. "This study is crucial for those suffering with the disease because it affirms that Pycnogenol® is more effective than prescription medication Precose® and supports the abundance of other research done on Pycnogenol® and diabetes."

        这项实验是在德国的乌兹堡完成的，Högger博士研究了碧萝芷®与阿尔法-葡萄糖苷酶的相互作用情况，阿尔法-葡萄糖苷酶的作用是分解食物中的碳水化合物。结果表明，碧萝芷®抑制阿尔法-葡萄糖苷酶的作用比人工抑制剂acarbose强190倍。Acarbose是一种常用的用于治疗II型糖尿病的处方药物，在欧洲销售的名字叫做Glucobay，在美国销售的名称为Precose。
        The study was conducted at the University of Wurzburg Germany. Dr. Högger investigated the interaction of Pycnogenol® with the enzyme alpha-glucosidase, which breaks down carbohydrates in a meal. Results revealed Pycnogenol® is 190 times more potent for inhibition of alpha-glucosidase than the synthetic inhibitor acarbose, a common prescription medication for treatment of type II diabetes (sold in Europe under the name Glucobay® and the United States under the name Precose®).

        碧萝芷®可以抑制肠道内的负责如淀粉和白糖等复合碳水化合物的消化的酶（阿尔法-葡萄糖苷酶）的活动能力。阿尔法-葡萄糖苷酶可以将碳水化合物分解成葡萄糖，葡萄糖会被吸收到血液中去。
        Pycnogenol® was shown to inhibit the intestinal enzymes (alpha-glucosidase) involved in the digestion of complex carbohydrates such as starch and normal table sugar. The alpha-glucosidase breaks down carbohydrates into glucose molecules which are then absorbed into the blood stream.

        “碧萝芷®中所含有的高浓度的前花青素（生物类黄酮）是发挥这一奇特作用的主要成分，”Högger博士说。Högger博士介绍道，较大分子的前花青素分子在抑制阿尔法-葡萄糖苷酶活性方面显得更为活跃，这就解释了碧萝芷®发挥作用的原因。“碳水化合物进入血液后在很长的一段时间内保持稳定，这就增强了每餐的效果，同时也推迟了饥饿感的出现。”
        "The high concentration of procyanidins (flavonoids) found in Pycnogenol® is responsible for demonstrating these excellent results," said Högger. According to Högger, the large procyanidin molecules were found to be particularly active for inhibiting the activity of alpha-glucosidase, thus demonstrating such notable results. "The carbohydrates enter the blood stream steadily over prolonged periods of time, which makes meals last longer and prolong satiety."

        在2004年进行的两项相对独立的实验中，实验都证实了碧萝芷®对于降低II型糖尿病患者血糖水平的功效。发表在2004年3月刊糖尿病保健杂志上的文章中写道，II型糖尿病患者服用碧萝芷®之后，其餐后血糖水平和空腹血糖水平均得到了降低。另外一篇发表在10月刊的生命科学杂志上的文章则记载了碧萝芷®在治疗糖尿病药物acarbose和metformin改善效果基础上，进一步降低了病人的血糖水平。
        In two separate studies conducted in 2004, Pycnogenol® was found to significantly lower blood sugar levels in type II diabetes patients. A study published in the March 2004 edition of Diabetes Care revealed that patients who supplemented with Pycnogenol® experienced lower blood sugar after meals and lower fasting blood sugar. Another study published in the October edition of Life Sciences revealed a significantly further lowered blood glucose level in patients who supplemented with Pycnogenol® while continuing their anti-diabetic medication with acarbose and metformin.

        这一研究成果开辟了碧萝芷®应用在治疗糖尿病、新陈代谢紊乱和肥胖症领域的新道路。“在美国，有7%的人口被确诊为糖尿病，不到五个人中就有一个人患有新陈代谢紊乱疾病，6千万美国成年人都属于肥胖人群，因此找到一种能够改善这些状况、提高生活治疗的天然、安全的产品非常有意义，”Högger说。
        This study opens new a venues for product development of Pycnogenol® in the field of diabetes, metabolic syndrome and obesity. “With seven percent of Americans diagnosed with diabetes, more than one in five people afflicted with metabolic syndrome, and 60 million U.S. adults considered obese, finding natural and safe options for managing these conditions and improving quality of life is a priority,” said Högger.